172 related articles for article (PubMed ID: 12923636)
1. Comparison of human lung cancer/SCID mouse tumor xenografts and cell culture growth with patient clinical outcomes.
Anderson TM; Hess SD; Egilmez NK; Nwogu CE; Lenox JM; Bankert RB
J Cancer Res Clin Oncol; 2003 Oct; 129(10):565-8. PubMed ID: 12923636
[TBL] [Abstract][Full Text] [Related]
2. Survival and treatment of non-small cell lung cancer stage I-II treated surgically or with stereotactic body radiotherapy: patient and tumor-specific factors affect the prognosis.
Mokhles S; Nuyttens JJ; Maat AP; Birim Ö; Aerts JG; Bogers AJ; Takkenberg JJ
Ann Surg Oncol; 2015 Jan; 22(1):316-23. PubMed ID: 24962941
[TBL] [Abstract][Full Text] [Related]
3. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy.
Higgins KA; Chino JP; Ready N; D'Amico TA; Berry MF; Sporn T; Boyd J; Kelsey CR
J Thorac Oncol; 2012 Jul; 7(7):1141-7. PubMed ID: 22617241
[TBL] [Abstract][Full Text] [Related]
4. Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers.
Tanvetyanon T; Robinson L; Sommers KE; Haura E; Kim J; Altiok S; Bepler G
J Thorac Oncol; 2010 Jul; 5(7):1018-24. PubMed ID: 20453687
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
[TBL] [Abstract][Full Text] [Related]
6. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.
Urban D; Bar J; Solomon B; Ball D
J Thorac Oncol; 2013 Jul; 8(7):940-6. PubMed ID: 23695418
[TBL] [Abstract][Full Text] [Related]
7. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the mammalian target of rapamycin: a novel biomarker for poor survival in resected early stage non-small cell lung cancer.
Dhillon T; Mauri FA; Bellezza G; Cagini L; Barbareschi M; North BV; Seckl MJ
J Thorac Oncol; 2010 Mar; 5(3):314-9. PubMed ID: 20093977
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.
Otsuka S; Klimowicz AC; Kopciuk K; Petrillo SK; Konno M; Hao D; Muzik H; Stolte E; Boland W; Morris D; Magliocco AM; Bebb DG
J Thorac Oncol; 2011 Jul; 6(7):1169-78. PubMed ID: 21623238
[TBL] [Abstract][Full Text] [Related]
12. The Frequency and Prognostic Impact of Pathological Microscopic Vascular Invasion According to Tumor Size in Non-Small Cell Lung Cancer.
Shimada Y; Saji H; Kato Y; Kudo Y; Maeda J; Yoshida K; Hagiwara M; Matsubayashi J; Kakihana M; Kajiwara N; Ohira T; Ikeda N
Chest; 2016 Mar; 149(3):775-85. PubMed ID: 26379115
[TBL] [Abstract][Full Text] [Related]
13. Ly6/uPAR-related protein C4.4A as a marker of solid growth pattern and poor prognosis in lung adenocarcinoma.
Jacobsen B; Muley T; Meister M; Dienemann H; Christensen IJ; Santoni-Rugiu E; Lærum OD; Ploug M
J Thorac Oncol; 2013 Feb; 8(2):152-60. PubMed ID: 23287851
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors for survival of stage I nonsmall cell lung cancer patients : a population-based analysis of 19,702 stage I patients in the California Cancer Registry from 1989 to 2003.
Ou SH; Zell JA; Ziogas A; Anton-Culver H
Cancer; 2007 Oct; 110(7):1532-41. PubMed ID: 17702091
[TBL] [Abstract][Full Text] [Related]
15. Lung carcinoma with rhabdoid component. A series of seven cases associated with uncommon types of non-small cell lung carcinomas and alveolar entrapment.
Izquierdo-Garcia FM; Moreno-Mata N; Herranz-Aladro ML; Cañizares MA; Alvarez-Fernandez E
Histol Histopathol; 2010 Oct; 25(10):1287-95. PubMed ID: 20712013
[TBL] [Abstract][Full Text] [Related]
16. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.
Saji H; Tsuboi M; Yoshida K; Kato Y; Nomura M; Matsubayashi J; Nagao T; Kakihana M; Usuda J; Kajiwara N; Ohira T; Ikeda N
J Thorac Oncol; 2011 Nov; 6(11):1865-71. PubMed ID: 21964529
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of TAZ expression in resected non-small cell lung cancer.
Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY
J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233
[TBL] [Abstract][Full Text] [Related]
18. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
[TBL] [Abstract][Full Text] [Related]
19. Survival differences by gender for resected non-small cell lung cancer: a retrospective analysis of 12,509 cases in a Japanese Lung Cancer Registry study.
Sakurai H; Asamura H; Goya T; Eguchi K; Nakanishi Y; Sawabata N; Okumura M; Miyaoka E; Fujii Y;
J Thorac Oncol; 2010 Oct; 5(10):1594-601. PubMed ID: 20736855
[TBL] [Abstract][Full Text] [Related]
20. Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Pluquet E; Cadranel J; Legendre A; Faller MB; Souquet PJ; Zalcman G; Perol M; Fraboulet G; Oliveiro G; De Fraipont F; Quoix E; Lantuejoul S; Milleron B; Moro-Sibilot D
J Thorac Oncol; 2010 Apr; 5(4):491-6. PubMed ID: 20195171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
